Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Total Liabilities
Everything the company owes to creditors and other parties.
Forte Biosciences, Inc.NASDAQ: FBRX
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 178.2% from a year ago
Total liabilities stood at $25.12M at the end of Q1 FY2026, up 178.2% from a year earlier and up 15.3% from the prior quarter. Over 3 fiscal years it compounded at +90.0% a year.
Context
- Total liabilities amounted to 37.4% of total assets at the end of Q1 FY2026, up 18.3 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +178.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 21.79M USD
- Year-over-year change
- +139.9%
- 4-year CAGR
- +87.6%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.79M | +139.9% |
| FY2024 | 2024-12-31 | 9.08M | +147.7% |
| FY2023 | 2023-12-31 | 3.67M | +15.3% |
| FY2022 | 2022-12-31 | 3.18M | +80.8% |
| FY2021 | 2021-12-31 | 1.76M | — |
Total Liabilities vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +178.2% is the highest of 10, against a peer median of -4.6%.
- Total liabilities amounts to 37.4% of total assets for FBRX, versus a peer median of 29.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $229.53M USD | -26.8% | -22.9% | 95.7% | |
| Mar 2026 | $105.21M USD | -4.6% | -20.4% | 36.9% | |
| Mar 2026 | $86.21M USD | -6.1% | -3.0% | 23.2% | |
| Mar 2026 | $25.12M USD | +178.2% | +90.0% | 37.4% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $24.13M USD | +25.4% | +20.8% | 106.3% |
| Mar 2026 | $22.32M USD | -37.3% | -11.2% | 14.3% | |
| Mar 2026 | CHF 19.15M CHF | +48.4% | -7.0% | 21.9% | |
| Mar 2026 | $18.14M USD | +41.4% | -14.7% | 12.6% | |
| Mar 2026 | $14.46M USD | +3.8% | +18.8% | 29.4% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $5.13M USD | -46.4% | +2.6% | 57.5% |
| Peer median (excluding FBRX) | — | -4.6% | -7.0% | 29.4% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.